The contract pharmaceutical development and manufacturing organization (CDMO) has completed its investment in its Durham, NC Clinical Services’ and Diagnostic Services’ capabilities.
The 24,000 square foot building is the company’s fourth at this location and provides additional office space for more than 100 new employees expected to be hired over the next three years.
“The main driver for growth globally (including NC) is the rise in biological investigational products, and data driven outcomes such as global temperature management and clinical site/patient driven innovations in the clinical supply chain,” Jonathan Calderwood, commercial development director, Almac Clinical Services, told us.
Almac announced a $5.2m investment in its US-based operations in 2016. The investment has expanded its clinical services operations as well as its diagnostics and clinical technologies services.
"Across the Almac companies there is a need to ensure that we are continually investing in staff and facilities to maintain the excellent standards that our customers have come to expect of us," Donna Christopher, global VP of operations told us at the time, adding that the company's activities in NC continue to grow, and as such, it is "seeking to meet that additional demand ."
Additionally, earlier this month, Almac’s Sciences Business Unit combined its capabilities with BioClin to form an analytical group spanning the UK, Europe, and North America.